$NAOV
NanoVibronix, Inc.

2022 Q3 Form 10-Q Financial Statement

#000149315222023047 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $97.00K $485.0K $272.0K
YoY Change -80.56% 52.52% 172.0%
Cost Of Revenue $17.00K $204.0K $166.0K
YoY Change -93.73% 85.45% 453.33%
Gross Profit $80.00K $281.0K $106.0K
YoY Change -64.91% 35.1% 32.5%
Gross Profit Margin 82.47% 57.94% 38.97%
Selling, General & Admin $955.0K $1.488M $1.152M
YoY Change -8.7% 31.1% -13.38%
% of Gross Profit 1193.75% 529.54% 1086.79%
Research & Development $49.00K $61.00K $66.00K
YoY Change -2.0% -4.69% 10.0%
% of Gross Profit 61.25% 21.71% 62.26%
Depreciation & Amortization $1.000K $0.00 $0.00
YoY Change -100.0%
% of Gross Profit 1.25% 0.0% 0.0%
Operating Expenses $1.004M $1.549M $1.218M
YoY Change -8.39% 29.19% -12.37%
Operating Profit -$924.0K -$1.268M -$1.112M
YoY Change 6.45% 27.95% -15.11%
Interest Expense -$16.00K -$18.00K -$13.00K
YoY Change -102.55% -99.34%
% of Operating Profit
Other Income/Expense, Net $0.00 -$18.00K $0.00
YoY Change -1900.0% -100.0%
Pretax Income -$940.0K -$1.286M -$1.125M
YoY Change -85.77% 484.55% -77.04%
Income Tax $15.00K $16.00K $7.000K
% Of Pretax Income
Net Earnings -$955.0K -$1.302M -$1.132M
YoY Change -85.69% 502.78% -76.99%
Net Earnings / Revenue -984.54% -268.45% -416.18%
Basic Earnings Per Share -$0.03 -$0.05 -$0.81
Diluted Earnings Per Share -$34.11K -$46.50K -$40.43K
COMMON SHARES
Basic Shares Outstanding 28.00M shares 28.00M shares 1.400M shares
Diluted Shares Outstanding 1.400M shares 1.400M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.972M $3.944M $5.990M
YoY Change -77.07% -30.47% -24.65%
Cash & Equivalents $1.972M $3.944M $5.990M
Short-Term Investments
Other Short-Term Assets $1.238M $1.175M $911.0K
YoY Change 107.37% 75.11% 333.81%
Inventory $1.553M $928.0K $355.0K
Prepaid Expenses
Receivables $226.0K $262.0K $134.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $4.989M $6.309M $7.390M
YoY Change -47.07% -4.18% -11.6%
LONG-TERM ASSETS
Property, Plant & Equipment $8.000K $7.000K $49.00K
YoY Change -69.23% -74.07% 63.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.000K $9.000K $224.0K
YoY Change -96.74% -95.93% 1.82%
Total Long-Term Assets $221.0K $233.0K $273.0K
YoY Change -8.3% -6.05% 13.75%
TOTAL ASSETS
Total Short-Term Assets $4.989M $6.309M $7.390M
Total Long-Term Assets $221.0K $233.0K $273.0K
Total Assets $5.210M $6.542M $7.663M
YoY Change -46.1% -4.24% -10.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $41.00K $173.0K $172.0K
YoY Change -33.87% -4.42% 72.0%
Accrued Expenses $28.00K $33.00K $44.00K
YoY Change 180.0% 230.0% 340.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.715M $2.053M $2.007M
YoY Change 544.74% 425.06% 128.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $341.0K $355.0K $395.0K
YoY Change -50.51% -84.41% -88.31%
Total Long-Term Liabilities $341.0K $355.0K $395.0K
YoY Change -50.51% -84.41% -88.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.715M $2.053M $2.007M
Total Long-Term Liabilities $341.0K $355.0K $395.0K
Total Liabilities $2.056M $2.408M $2.402M
YoY Change 115.29% -9.75% -43.62%
SHAREHOLDERS EQUITY
Retained Earnings -$60.33M -$59.37M
YoY Change
Common Stock $28.00K $28.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.154M $4.134M $5.261M
YoY Change
Total Liabilities & Shareholders Equity $5.210M $6.542M $7.663M
YoY Change -46.1% -4.24% -10.9%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$955.0K -$1.302M -$1.132M
YoY Change -85.69% 502.78% -76.99%
Depreciation, Depletion And Amortization $1.000K $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$1.964M -$1.999M -$3.740M
YoY Change 209.78% 4.11% 293.68%
INVESTING ACTIVITIES
Capital Expenditures -$2.000K -$2.000K
YoY Change 100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.000K -$2.000K
YoY Change 100.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -1.964M -1.999M -$3.740M
Cash From Investing Activities -2.000K -2.000K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -1.966M -2.001M -$3.740M
YoY Change -167.17% -13.53% -913.04%
FREE CASH FLOW
Cash From Operating Activities -$1.964M -$1.999M -$3.740M
Capital Expenditures -$2.000K -$2.000K
Free Cash Flow -$1.962M -$1.997M -$3.740M
YoY Change 209.95% 4.12% 293.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001326706
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
usd
CY2022Q2 NAOV Gain Loss On Purchase Of Warrants
GainLossOnPurchaseOfWarrants
usd
NAOV Gain Loss On Purchase Of Warrants
GainLossOnPurchaseOfWarrants
usd
CY2022Q2 NAOV Warrant Modification Expense
WarrantModificationExpense
usd
CY2021Q2 NAOV Warrant Modification Expense
WarrantModificationExpense
usd
NAOV Warrant Modification Expense
WarrantModificationExpense
usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
usd
NAOV Warrant Modification Expense
WarrantModificationExpense
usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
usd
NAOV Gain Loss On Purchase Of Warrants
GainLossOnPurchaseOfWarrants
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
NAOV Shares Issued From Exercise Of Warrants Previously Classified As Derivative Liability
SharesIssuedFromExerciseOfWarrantsPreviouslyClassifiedAsDerivativeLiability
usd
NAOV Reclass Liability To Equity After Increase In Authorized Shares
ReclassLiabilityToEquityAfterIncreaseInAuthorizedShares
usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36445
dei Entity Registrant Name
EntityRegistrantName
NanoVibronix, Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
01-0801232
dei Entity Address Address Line1
EntityAddressAddressLine1
525 Executive Blvd
dei Entity Address City Or Town
EntityAddressCityOrTown
Elmsford
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10523
dei City Area Code
CityAreaCode
(914)
dei Local Phone Number
LocalPhoneNumber
233-3004
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
NAOV
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27997793 shares
CY2022Q2 us-gaap Cash
Cash
3944000 usd
CY2021Q4 us-gaap Cash
Cash
7737000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
262000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
200000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1175000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
230000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
928000 usd
CY2022Q2 us-gaap Assets
Assets
6542000 usd
CY2021Q4 us-gaap Assets
Assets
8622000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
175000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
173000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
87000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56937000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4134000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
6309000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
8342000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19000 usd
CY2022Q2 NAOV Severance Assets Noncurent
SeveranceAssetsNoncurent
184000 usd
CY2021Q4 NAOV Severance Assets Noncurent
SeveranceAssetsNoncurent
207000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
49000 usd
CY2022Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
233000 usd
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
280000 usd
CY2022Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
1803000 usd
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
1723000 usd
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
44000 usd
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
44000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
33000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
49000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2053000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1903000 usd
CY2022Q2 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
225000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
253000 usd
CY2022Q2 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
130000 usd
CY2021Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
153000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
2408000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
2309000 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27997793 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27997793 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27997793 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27997793 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
28000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
28000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
63468000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
63162000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
60000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59371000 usd
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
333000 usd
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
296000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6313000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6542000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8622000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
485000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
318000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
757000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
421000 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
204000 usd
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
110000 usd
us-gaap Cost Of Revenue
CostOfRevenue
370000 usd
us-gaap Cost Of Revenue
CostOfRevenue
136000 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
281000 usd
CY2021Q2 us-gaap Gross Profit
GrossProfit
208000 usd
us-gaap Gross Profit
GrossProfit
387000 usd
us-gaap Gross Profit
GrossProfit
285000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
127000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
128000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
543000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
607000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1155000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
839000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2097000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1855000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
1549000 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
1199000 usd
us-gaap Operating Expenses
OperatingExpenses
2767000 usd
us-gaap Operating Expenses
OperatingExpenses
2590000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1268000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-991000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2380000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2305000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000 usd
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
706000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1242000 usd
CY2021Q2 NAOV Gain Loss On Purchase Of Warrants
GainLossOnPurchaseOfWarrants
64000 usd
NAOV Gain Loss On Purchase Of Warrants
GainLossOnPurchaseOfWarrants
64000 usd
NAOV Warrant Modification Expense
WarrantModificationExpense
1627000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1286000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-220000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2411000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5116000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
14000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
51000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1302000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-216000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2434000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5133000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5133000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27997793 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24776302 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27997793 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24476551 shares
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1302000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-216000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2434000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5133000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
46000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
8000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1348000 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-230000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2485000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5141000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
4347000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
35000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-216000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
4164000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2394000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
79000 usd
NAOV Exercise Of Warrants
ExerciseOfWarrants
3494000 usd
NAOV Adjustments To Additional Paid In Capital Reclass Liability To Equity
AdjustmentsToAdditionalPaidInCapitalReclassLiabilityToEquity
3337000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5133000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
4164000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
5261000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
83000 usd
CY2022Q2 NAOV Exercise Of Warrants
ExerciseOfWarrants
137000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-45000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1302000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4134000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6313000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
171000 usd
NAOV Exercise Of Warrants
ExerciseOfWarrants
135000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-51000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2434000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4134000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2434000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
86000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
37000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
306000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
208000 usd
NAOV Warrant Modification Expense
WarrantModificationExpense
1627000 usd
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-10000 usd
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-2000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1242000 usd
NAOV Gain Loss On Purchase Of Warrants
GainLossOnPurchaseOfWarrants
64000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
62000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
945000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
404000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
753000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
60000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
80000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-341000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-23000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
30000 usd
NAOV Increase Decrease In Accrued Severance Pay Net
IncreaseDecreaseInAccruedSeverancePayNet
-5000 usd
NAOV Increase Decrease In Accrued Severance Pay Net
IncreaseDecreaseInAccruedSeverancePayNet
-3000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3740000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2870000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1406000 usd
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
388000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1018000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-51000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-7000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3793000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1861000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7737000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7533000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3944000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5672000 usd
NAOV Shares Issued From Exercise Of Warrants Previously Classified As Derivative Liability
SharesIssuedFromExerciseOfWarrantsPreviouslyClassifiedAsDerivativeLiability
2087000 usd
NAOV Reclass Liability To Equity After Increase In Authorized Shares
ReclassLiabilityToEquityAfterIncreaseInAuthorizedShares
3337000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
220000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
99000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
306000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
208000 usd
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
250000 shares
CY2022Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2029-06-14
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_80B_eus-gaap--NatureOfOperations_zxIMGpEGZXxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_822_zl5BSmHYMk27">DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix, Inc. (the “Company”), a Delaware corporation, commenced operations on October 20, 2003 and is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s principal research and development activities are conducted in Israel through its wholly owned subsidiary, NanoVibronix (Israel 2003) Ltd., a company registered in Israel, which commenced operations in October 2003.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3740000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3740000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3944000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zu2o6u0uut38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zMLzkzaSfJZj">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believe that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
51000 usd
us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
7000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
13845 shares
CY2022Q2 us-gaap Share Price
SharePrice
0.78
CY2021Q2 us-gaap Share Price
SharePrice
1.04
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.78
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0232 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0049 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.279 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.815 pure
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.00
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
135000000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5219346 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7726961 shares
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
485000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
318000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
757000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
421000 usd
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
8000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
10000 usd
CY2022Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
9000 usd
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2000 usd
CY2021Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
23000 usd

Files In Submission

Name View Source Status
0001493152-22-023047-index-headers.html Edgar Link pending
0001493152-22-023047-index.html Edgar Link pending
0001493152-22-023047.txt Edgar Link pending
0001493152-22-023047-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
naov-20220630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
naov-20220630_def.xml Edgar Link unprocessable
naov-20220630_cal.xml Edgar Link unprocessable
naov-20220630_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
naov-20220630_pre.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending